# argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer Canonical URL: https://biopharmsignal.com/news/ARGX/argenx-announces-results-of-annual-general-meeting-and-board-of-directors-appoin-3abcc261 Ticker: ARGX Company: Argenx Source: Argenx Published: 2026-05-06 20:01 EST ## Summary Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global... ## Article Body Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today announced the results of the Annual General Meeting of shareholders and the Board of Directors’ appointment of Karen Massey as Chief Executive Officer and Tim Van Hauwermeiren as Chairperson of the Board of Directors. “Karen has earned the full confidence of the Board of Directors and our shareholders,” said Tim Van Hauwermeiren, Chair of the Board of Directors. “She is a proven leader who has played a central role in shaping argenx’s execution and long-term growth strategy. Karen leads with our responsibility to patients, the argenx culture, and a vision to continue to build our pipeline. I look forward to supporting Karen and the leadership team as argenx enters its next phase of growth.” Karen Massey joined argenx in March 2023 as Chief Operating Officer and will succeed Tim Van Hauwermeiren, who co-founded argenx and has served as Chief Executive Officer since 2008. Her appointment by the Board of Directors as CEO follows shareholder approval of her appointment as executive director of the Board of Directors. The Board of Directors also appointed Tim Van Hauwermeiren as Chairperson of the Board of Directors, effective immediately, following his appointment as non-executive director to the Board of Directors at the General Meeting. 90.9% of the Company’s share capital was represented at the General Meeting. All items on the agenda received the required majority of votes in favor for approval, including: argenx 2025 remuneration report argenx annual report and annual accounts for the financial year ending December 31, 2025 Allocation of the Company’s 2025 profits to the retained earnings Karen Massey has been appointed as an executive director to the Board of Directors for a term of 4 years Tim Van Hauwermeiren has been appointed as a non-executive director to the Board of Directors for a term of 4 years Ana Céspedes has been reappointed as non-executive director to the Board of Directors for a term of 4 years Camilla Sylvest has been reappointed as non-executive director to the Board of Directors for a term of 4 years Pam Klein has been reappointed as non-executive director to the Board of Directors for a term of 2 years Authorization to issue shares and grant rights to subscribe for shares in the share capital of the Company for up to 10% of the outstanding share capital at the date of the meeting and for a period of 18 months from the meeting and to limit or exclude statutory pre-emptive rights The voting result and all documents relating to the shareholders’ meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings . About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn , Instagram , Facebook , and YouTube . For further information, please contact: Media: Ben Petok bpetok@argenx.com Investors: Alexandra Roy aroy@argenx.com ## Recent Company News - 2026-07-27 05:00 EST — [argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline](https://biopharmsignal.com/news/ARGX/argenx-to-acquire-forte-biosciences-inc-adding-first-in-class-anti-cd122-antibod-fae8b638) — Source: Argenx - 2026-07-23 05:00 EST — [argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update](https://biopharmsignal.com/news/ARGX/argenx-reports-half-year-2026-financial-results-and-provides-second-quarter-busi-a7cfe76d) — Source: Argenx - 2026-07-16 05:00 EST — [argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026](https://biopharmsignal.com/news/ARGX/argenx-to-report-half-year-2026-financial-results-and-second-quarter-business-up-391e9c59) — Source: Argenx - 2026-06-23 05:00 EST — [argenx to Host Autoimmune Myositis R&D Webinar](https://biopharmsignal.com/news/ARGX/argenx-to-host-autoimmune-myositis-r-d-webinar-30608012) — Source: Argenx - 2026-06-03 05:00 EST — [argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026](https://biopharmsignal.com/news/ARGX/argenx-presents-new-efgartigimod-data-showing-long-term-sustained-patient-benefi-e5897167) — Source: Argenx ## Related News - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)